Lung cancer is among the most fatal malignancies worldwide, with approximately 85% of diagnosed cases being non-small-cell lung cancer (NSCLC). Despite the considerable progress in surgical, chemotherapeutic, radiotherapeutic, and immunological treatments, the prognosis of NSCLC remains poor due to late-stage diagnosis...
Areena Turk, Mohit Mishra, V. Kasana et al.· Pharmaceuticals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.